<DOC>
	<DOCNO>NCT02635607</DOCNO>
	<brief_summary>The purpose study compare effectiveness Day-5 fixed administration GnRH antagonist versus flexible administration GnRH antagonist ovarian stimulation Chinese woman predict high ovarian response , hypotheses number oocyte retrieve fix protocol inferior GnRH antagonist flexible protocol .</brief_summary>
	<brief_title>Effectiveness Safety Study Fixed Versus Flexible Gonadotropin-releasing Hormone Antagonist Protocol</brief_title>
	<detailed_description>The investigator responsible analyze study data . This study design open-label fashion , thus , blindness maintain study . The database lock medical/scientific review complete , protocol violator identify , data declare complete . Statistical Methods For primary endpoint , mean standard deviation ( SD ) number oocyte present . The between-group difference correspond 95 % confidence interval ( CI ) ( Day-5 fix protocol - flexible protocol ) calculate use two-sample t-test assumption sample data normally distribute . A test normality perform prior analysis primary endpoint possible nonparametric adjustment make skew data term primary analysis . The non-inferiority establish low bound 95 % CI treatment difference two group ( Day-5 fix protocol - flexible protocol ) exceed -3.0 . The superiority may claim Day-5 fix protocol lower bound 95 % CI treatment difference 0.0 . For secondary endpoint categorical variable , number percentage event calculate displayed . Clinical ongoing pregnancy rate separately calculate present . Between-group comparison make Chi-square test correspond 95 % CI present use Miettinen-Nurminen method number observe event least 4 . Mean SD summarize continuous variable term secondary outcome measure . A treatment difference study group make use two-sample t-test nonparametric test whenever appropriate . The number subject report adverse experience ( AE ) incidence individual AEs count present . Fisher 's exact test perform compare treatment group . Demographics subject 's relevant medical history summarize descriptive statistic . All statistical analysis two-sided significant level p value le 0.05 , unless otherwise specify . Sample Size : A sample size 200 ( 1:1 allocation ) achieve 80 % power detect non-inferiority Day-5 fixed-dose regimen compare flexible protocol margin -3 oocytes retrieve ( 3 oocyte few control group ) , use one-sided , two-sample t-test Mann-Whitney test adjustment significance level 0.025 . The true difference mean assume 0.0 standard deviation intervention arm 6.8 . The pre-mature discontinuation rate set approximately 15 % study .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Hormone Antagonists</mesh_term>
	<mesh_term>Ganirelix</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>1 . Have indication COS IVF/ICSI ; 2. ＜35 year old ; 3. BMI 1825kg/m2 ; 4. regular menstruation range 2435 day ; 5. fulfill one three criterion follow : number oocytes retrieved＞15 previous COS cycle ; Serum AMH ( examine menstrual cycle day 2 ) ＞3.52ng/ml ; antral follicle count ( AFC ) ( examine ultrasonic menstrual cycle day 2 ) ＞16 6. willingness give inform consent 1 . Presence unilateral ovary absence ; 2 . Any difficulty oocyte pickup abnormal condition ovary pelvic cavity ; 3 . Women clinically relevant pathology could impair embryo implantation pregnancy continuation ( uterine malformation , intermural uterine fibroids＞3cm , intrauterine adhesion , etc ) ; 4 . Women polycystic ovary syndrome ( PCOS ) diagnose Rotterdam consensus criterion ( Rotterdam , 2004 ) 5 . Other know abnormal ovulation disorder ( include limit adrenal gland disease , thyroid disease hyperprolactinemia ) ; 6 . A history recurrent miscarriage previous IVF cycle failure＞2 ; 7 . A history ovarian hyporesponse previous ovarian stimulation ; 8 . Women clinical/socioeconomic factor preclude completion study discretion investigator .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>GnRH antagonist</keyword>
	<keyword>fix protocol</keyword>
	<keyword>flexible protocol</keyword>
</DOC>